Results 151 to 160 of about 212,106 (307)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors. [PDF]

Ther Adv Med Oncol
Nguyen T, Nguyen Hoang VA, Nguyen TH, Tran TH, Nguyen N, Le Vo TT, Nguyen DS, Giang H, Nguyen HN, Tu LN.   +9 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Evaluation of Minimal Residual Disease in Patients with Neuroblastoma. [PDF]

Mol Diagn Ther
Yamamoto N, Ishizawa K, Umemoto M, Nishimura A, Fujikawa T, Inoue S, Nakatani N, Tamura A, Nino N, Uemura S, Hasegawa D, Kosaka Y, Nishimura N.   +12 more
europepmc   +1 more source

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study [PDF]

Martijn W. C. Verbeek, Michaela Reiterová, Anna Laqua, Beatriz Rodríguez‐Roca, Łukasz Sędek, Chiara Buracchi, Malicorne Buysse, Elen Oliveira, Robby Engelmann, Joana Desterro, Anja X. De Jong, Sebastian Böettcher, Romana Jugooa, Susana Bárrena, Saskia Kohlscheen, Stefan Nierkens, Joana G. Rodriques, Mattias Hofmans, Giuseppe Gaipa, Elaine Sobral de Costa, Ester Mejstříková, Tomasz Szczepański, Monika Brüggemann, Jacques J. M. van Dongen, Alberto Órfão, Vincent H. J. van der Velden   +25 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. [PDF]

Cancers (Basel)
Theocharopoulos C, Machairas N, Ziogas IA, Mungo B, Del Chiaro M, Glatzounis GK, Schulick R, Sotiropoulos GC.   +7 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment. [PDF]

Transl Oncol
Xie LJ, Fu LL, Liu SC, Bai CS, Xu BC, He XW, Lin HF, Zeng YC, Tang WJ.   +8 more
europepmc   +1 more source

Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer [PDF]

Jorge Martín-Arana, Francisco Gimeno-Valiente, Tenna Vesterman Henriksen, Blanca García-Micó, B. Martínez-Castedo, Valentina Gambardella, Carolina Martínez‐Ciarpaglini, Brenda Palomar-De Lucas, Marisol Huerta, Daniel G. Camblor, M. Bartolomé, Juan Antonio Carbonell‐Asins, Amanda Frydendahl, Kåre Andersson Gotschalck, Tania Fleitas, R. Tébar-Martínez, D Moro, Vicente Pla, Leticia Pérez‐Santiago, José Martín‐Arévalo, David Casado, Stephanie García‐Botello, Alejandro Espí, Susana Roselló, Desamparados Roda, Claus L. Andersen, Andrés Cervantes, Noelia Tarazona   +27 more
openalex   +1 more source